Drug Trial Radar · NCT04471727
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
232
Planned (sponsor's estimate)
Start
Dec 14, 2020
Primary completion
Jan 28, 2028
Study completion Jan 28, 2028
Sponsor
- Lead sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jul 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).
Conditions
- Small-Cell Lung Cancer
- Neuroendocrine Carcinoma
Interventions
GocatamigBiological
IV infusion
AtezolizumabBiological
IV infusion
Ifinatamab Deruxtecan (I-DXd)Biological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who experience an adverse eventTime frame: Up to ~4 years
- Percentage of participants who discontinue due to an adverse eventTime frame: Up to ~4 years
- Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXdTime frame: Up to ~4 years
- Maximum concentration (Cmax) of GocatamigTime frame: At designated time points up to ~4 years
- Cmax of AtezolizumabTime frame: At designated time points up to ~4 years
- Cmax of I-DXdTime frame: At designated time points up to ~4 years
- Time to maximum concentration (Tmax) of GocatamigTime frame: At designated time points up to ~4 years
- Tmax of atezolizumabTime frame: At designated time points up to ~4 years
- Tmax of I-DXdTime frame: At designated time points up to ~4 years
- Area under the concentration-time curve over the dosing interval t (AUCt) of GocatamigTime frame: At designated time points up to ~4 years
- AUCt of atezolizumabTime frame: At designated time points up to ~4 years
- AUCt of I-DXdTime frame: At designated time points up to ~4 years
- Area under the concentration-time curve extrapolated to infinity (AUCinf) of GocatamigTime frame: At designated time points up to ~4 years
- AUCinf of atezolizumabTime frame: At designated time points up to ~4 years
- AUCinf of I-DXdTime frame: At designated time points up to ~4 years
- Terminal half-life (t1/2) of GocatamigTime frame: At designated time points up to ~4 years
- t1/2 of atezolizumabTime frame: At designated time points up to ~4 years
- t1/2 of I-DXdTime frame: At designated time points up to ~4 years
- Single dose clearance (CL) of GocatamigTime frame: At designated time points up to ~4 years
- CL of atezolizumabTime frame: At designated time points up to ~4 years
- CL of I-DXdTime frame: At designated time points up to ~4 years
- Steady state maximum concentration (Cmax,ss) of GocatamigTime frame: At designated time points up to ~4 years
- Cmax,ss of atezolizumabTime frame: At designated time points up to ~4 years
- Cmax,ss of I-DXdTime frame: At designated time points up to ~4 years
- Steady state Ctrough (Ctrough,ss) of GocatamigTime frame: At designated time points up to ~4 years
- Ctrough,ss of atezolizumabTime frame: At designated time points up to ~4 years
- Ctrough,ss of I-DXdTime frame: At designated time points up to ~4 years
- Steady state time to maximum concentration (Tmax,ss) of GocatamigTime frame: At designated time points up to ~4 years
- Tmax,ss of atezolizumabTime frame: At designated time points up to ~4 years
- Tmax,ss of I-DXdTime frame: At designated time points up to ~4 years
- Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of GocatamigTime frame: At designated time points up to ~4 years
- AUCt,ss of atezolizumabTime frame: At designated time points up to ~4 years
- AUCt,ss of I-DXdTime frame: At designated time points up to ~4 years
- Steady state t1/2 (t1/2,ss) of GocatamigTime frame: At designated time points up to ~4 years
- t1/2,ss of Gocatamig with atezolizumabTime frame: At designated time points up to ~4 years
- t1/2,ss of IDXdTime frame: At designated time points up to ~4 years
- Steady state CL (CL,ss) of GocatamigTime frame: At designated time points up to ~4 years
- CL,ss of Gocatamig with atezolizumabTime frame: At designated time points up to ~4 years
- CL,ss of I-DXdTime frame: At designated time points up to ~4 years
- Steady state volume of distribution (V,ss) of GocatamigTime frame: At designated time points up to ~4 years
- V,ss of atezolizumabTime frame: At designated time points up to ~4 years
- V,ss of I-DXdTime frame: At designated time points up to ~4 years
- Steady state accumulation ratio (AC) of GocatamigTime frame: At designated time points up to ~4 years
- AC of atezolizumabTime frame: At designated time points up to ~4 years
- AC of I-DXdTime frame: At designated time points up to ~4 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
University of California San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Center
Detroit, Michigan
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Providence
Portland, Oregon
Tennessee Oncology
Nashville, Tennessee
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.